Dogwood Therapeutics (DWTX) Free Cash Flow (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Free Cash Flow of -$4.6 million for Q1 2026, up 2.04% year-over-year from -$4.5 million in Q1 2025, and down 26.12% quarter-over-quarter from -$3.6 million in Q4 2025.
Dogwood Therapeutics (DWTX) Free Cash Flow (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Free Cash Flow for 7 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 2.04% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at -$15.5 million (down 23.83% YoY), while the FY2025 annual figure was -$15.6 million, down 77.67% from the prior year.
- Free Cash Flow eased to -$4.6 million in Q1 2026 per DWTX's latest filing, from -$3.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$742414.0 in Q2 2023 and bottomed at -$6.1 million in Q4 2024.
- Historically, Free Cash Flow has averaged -$2.7 million across 5 years, with a median of -$2.7 million in 2022.
- Annual changes were most pronounced in 2023 — Free Cash Flow surged 79.7% — and 2025, when it tumbled 399.52%.
- Dogwood Therapeutics' Free Cash Flow stood at -$2.7 million in 2022, then surged by 45.0% to -$1.5 million in 2023, then sank by 317.34% to -$6.1 million in 2024, then soared by 40.68% to -$3.6 million in 2025, then decreased by 26.12% to -$4.6 million in 2026.
- Business Quant data shows DWTX's Free Cash Flow at -$4.6 million in Q1 2026, -$3.6 million in Q4 2025, and -$3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | -3.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.59 Mn |
| Mar 31, 2026 | -4.59 Mn |
| Dec 31, 2025 | -3.64 Mn |
| Dec 31, 2025 | -3.64 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Jun 30, 2025 | -4.03 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Dec 31, 2024 | -6.13 Mn |
| Dec 31, 2024 | -6.13 Mn |
| Sep 30, 2024 | -910,137.00 |
| Sep 30, 2024 | -910,137.00 |
| Jun 30, 2024 | -811,746.00 |
| Jun 30, 2024 | -811,746.00 |
| Mar 31, 2024 | -937,414.00 |
| Mar 31, 2024 | -937,414.00 |
| Dec 31, 2023 | -1.47 Mn |
| Dec 31, 2023 | -1.47 Mn |